First patient treated in Phase I VXM01 glioblastoma trial
Vaximm's VXM01 is an oral T-cell immunotherapy that targets the tumour-specific vasculature and certain immune-suppressive cells...
List view / Grid view
Vaximm's VXM01 is an oral T-cell immunotherapy that targets the tumour-specific vasculature and certain immune-suppressive cells...
The Swiss-German biotech company, VAXIMM AG, has announced the enrolment of its first patient in a Phase 2a clinical trial for immunotherapy, VXM01.
Phase I study evaluating safety and tolerability of VXM01 in pancreatic cancer...